Table 1 Baseline characteristics and medication of SLE patients (n = 34) and healthy controls (HC, n = 18) included in the study.
From: Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus
SLE patients | HC | P-value | |
|---|---|---|---|
Total number | 34 | 18 | |
Women/men | 28/6 | 15/3 | ns |
Age (years, mean ± SD) | 41 ± 14 | 35 ± 11 | ns |
SLEDAI (median (range)) | 4 (0 to 17) | ||
C3, g/l (median, range) | 0.82 (0.37 to 1.45) | ||
C4, g/l (median, range) | 0.21 (0.04 to 0.30) | ||
Anti-dsDNA, E/ml (median, range) | 165 (4 to 1,000) | ||
Treatment, n | 18 | ||
None | 4 | ||
Glucocorticoids, n | 23 | ||
median dose (range), dose (mg/day) | 5 (3.75 to 60) | ||
Immunosupressive/immunmodulating, n | |||
Hydroxychloroquine | 17 | ||
median dose (range), users (mg/day) | 400 (200 to 600) | ||
Methotrexate | 2 | ||
median dose (range), users (mg/week) | 15 (5 to 25) | ||
Azathioprine | 12 | ||
median dose (range), users (mg/day) | 112.5 (50 to 150) | ||
MMF | 4 | ||
median dose (range), users (mg/day) | 2,500 (1,000 to 3,000) |